Danaher Corporation 10-Qquarter ended 2026-09-25

Executive Summary

Danaher sells laboratory, bioprocessing and diagnostic tools to researchers, drugmakers and healthcare providers, earning most revenue from recurring purchases. Its ≈$9.8B Masimo acquisition expands Diagnostics into acute-care patient monitoring. Underlying demand improved across all three segments, but acquisitions supplied most reported growth and respiratory testing remained weak. Continuing-operations earnings rose 33%, helped materially by tax settlements rather than operating improvement alone. Investors now face a larger monitoring opportunity alongside heavier borrowing and acquisition-integration demands.

What's Happening in the Business

• Diagnostics expansion: Masimo joined on 6/10/2026, adding patient-monitoring technology and ≈$1.5B in annual revenue based on 2025 sales. After quarter-end, Danaher acquired StatLab for ≈$1.4B, adding diagnostic laboratory products.
• Bioprocessing recovery: Biotechnology core sales grew 5%, led by consumables and improving equipment demand, while discovery and medical sales declined. Life Sciences benefited from consumables and filtration demand from microelectronics and aerospace.
• Uneven diagnostics demand: Core sales grew 0.5%, or 7% excluding respiratory testing. Clinical diagnostics growth offset weaker respiratory demand, while China procurement and reimbursement changes, promotions and competition pressured pricing.
• Geographic improvement: High-growth markets supplied ≈31% of quarterly sales and delivered 10% core growth. China returned to growth, but developed-market core sales were flat as North American respiratory weakness offset Western Europe.
• Growth measurement: Danaher began excluding customer tariff refunds from core sales, its measure of underlying growth. Quarterly core growth was 3%, or 5.5% excluding respiratory testing; the latter isolates the respiratory decline rather than describing the whole business.

Key Financial Highlights

• Earnings quality: Q3 included $263M of discrete tax benefits. Nine-month comparisons also benefited from $548M of prior-year impairment charges; neither represents current operating improvement.
• Acquisition costs: Masimo inventory fair-value step-up charges were $84M in Q3, depressing Diagnostics profit despite revenue growth. A $52M Biotechnology facility impairment also affected the quarter.
• Cash conversion: Nine-month FCF was $3.98B after $761M of capital expenditures. Working-capital and other cash uses partly offset higher earnings.
• Capital returns: Repurchases of $894M accompanied a 0.5% net decline in shares outstanding. Nine-month stock-based compensation was $266M; management expects a separate $185M noncash Q4 charge following the Rales brothers’ award waivers.
• Other earnings support: Tariff refunds, net of customer refunds, benefited net earnings by less than $100M, adding another nonrecurring influence.

Risk Assessment

• Acquisition value: Masimo’s preliminary allocation included $4.88B of goodwill and $5.01B of identifiable intangibles; company-wide tangible common equity was $(14.7)B, increasing exposure to impairment if acquired businesses disappoint.
• Financing: Higher borrowings doubled quarterly interest expense to $135M; $4.71B of euro commercial paper creates refinancing exposure, although cash and undrawn facilities provide liquidity.
• Inherited litigation: Masimo’s $634M Apple patent award plus ≈$184M interest remains under appeal, while a Department of Justice matter has a possible loss range of ≈$5M–$40M and other claims remain difficult to estimate.
• Diagnostics demand and pricing: Uncertain respiratory-season purchasing and China reimbursement pressure could offset growth elsewhere in diagnostics.
• Conflict and tariffs: Middle East delivery delays and higher logistics costs already affect operations; escalation or replacement tariffs could further disrupt supply and customer demand.

This 10-Q lists only the risk factors that changed since the annual report. Full list: the company's 10-Ks on SEC.

What to Watch

• Masimo integration: Diagnostics revenue grew while profit fell under acquisition charges and dilution; subsequent results should show whether monitoring growth translates into profit as those charges subside.
• Bioprocessing recovery: Consumables and improving equipment demand lifted Biotechnology core sales; sustained growth would support recovery, while renewed equipment weakness would challenge it.
• Diagnostics beyond respiratory testing: Non-respiratory core growth outpaced the segment; later filings should show whether clinical diagnostics can keep overcoming respiratory weakness and China pricing pressure.
• Debt reduction: Acquisition financing lifted debt materially; continued cash generation and lower borrowing would ease financing risk, while persistently elevated debt and interest costs would constrain flexibility.